Risk of alveolar hemorrhage in patients with primary pulmonary hypertension: Anticoagulation and epoprostenol therapy

Aiko Ogawa, Hiromi Matsubara, Hideki Fujio, Katsumasa Miyaji, Kazufumi Nakamura, Hiroshi Morita, Hironori Saito, Kengo Fukushima Kusano, Tetsuro Emori, Hiroshi Date, Tohru Ohe

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Anticoagulation therapy and continuous intravenous infusion of epoprostenol are the standard treatment for primary pulmonary hypertension (PPH). Because epoprostenol has an antiplatelet effect, concomitant use of an anticoagulant could increase the likelihood of hemorrhagic complications. Methods and Results: In the present study, 31 consecutive patients with PPH (10 men, 21 women, mean±SD age, 28.5±10.1 years) treated with anticoagulation and epoprostenol between April 1999 and December 2003 were retrospectively evaluated. Clinical and hematological data at the time of the bleeding episode were retrieved from the medical records. Nine patients (22.6%) experienced 11 bleeding episodes: 9 episodes (81.8%) were alveolar hemorrhage and 2 patients were in severe respiratory distress. The mean dose of epoprostenol at the time of the first bleeding episode was 89.0±40.5 ng·kg-1·min-1 (range, 28.1-164.0). More of the patients who did not have a bleeding episode remain alive than did patients with bleeding episodes (59% vs 33%) nor did they require lung transplantation. Conclusions: A considerable number of patients with PPH who received combined anticoagulant and high-dose epoprostenol therapy developed alveolar hemorrhage, which can be fatal.

Original languageEnglish
Pages (from-to)216-220
Number of pages5
JournalCirculation Journal
Volume69
Issue number2
DOIs
Publication statusPublished - Feb 1 2005

Keywords

  • Alveolar hemorrhage
  • Anticoagulation
  • Epoprostenol
  • Primary pulmonary hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Risk of alveolar hemorrhage in patients with primary pulmonary hypertension: Anticoagulation and epoprostenol therapy'. Together they form a unique fingerprint.

  • Cite this

    Ogawa, A., Matsubara, H., Fujio, H., Miyaji, K., Nakamura, K., Morita, H., Saito, H., Kusano, K. F., Emori, T., Date, H., & Ohe, T. (2005). Risk of alveolar hemorrhage in patients with primary pulmonary hypertension: Anticoagulation and epoprostenol therapy. Circulation Journal, 69(2), 216-220. https://doi.org/10.1253/circj.69.216